Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2014, Pages 51-57

  Sicras Mainar, Antoni ^a   Maurino, Jorge ^b   Ruiz Beato, Elena ^b   Navarro Artieda, Ruth ^c  

^a Badalona Serveis Assistencials SA   (Spain)

^b Roche Farma SA   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cardiovascular risk; Comorbidity; Metabolic abnormalities; Negative symptoms; Physical illness; Schizophrenia

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; RETROSPECTIVE STUDY; SEX RATIO;

EID: 84937548858     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S75449     Document Type: Article

References (31)

1. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129–2143.
2. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425–448.
3. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012;25:83–88.
4. Leucht S. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand. 2007;116:317–333.
5. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24:412–424.
6. Fervaha G, Foussias G, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia. Eur Psychiatry. 2014;29:449–455.
7. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692.
8. Bobes J, Arango C, Garcia-Garcia M, Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010;71:280–286.
9. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147–150.
10. Arango C, Garibaldi G, Marder SR. Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res. 2013;150:346–352.
11. Papanastasiou E. The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol. 2013;3:33–51.
12. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.
13. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res. 2007;94:375–376.
14. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutiérrez J, Navarro-Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry. 2008;23:100–108.
15. Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39:295–305.
16. Sicras-Mainar A, Maurino J, Ruíz-Beato E, Navarro-Artieda R. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study. BMC Psychiatry. 2014;14:225.
17. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538–546.
18. Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative and disorganized thought symptoms. Psychiatry Res. 2014;218:219–224.
19. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
20. Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452–472.
21. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
22. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419.
23. Sánchez-Araña Moreno T, Touriño-González R, Hernández-Fleta JL, León-Pérez P. Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands. Actas Esp Psiquiatr. 2007;35:359–367.
24. Bernardo M, Cañas F, Banegas JR, Casademont J, Riesgo Y, Varela C. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry. 2009;24:431–441.
25. Medeiros-Ferreira L, Obiols JE, Navarro-Pastor JB, Zúñiga-Lagares A. Metabolic syndrome and health-related quality of life in patients with schizophrenia. Actas Esp Psiquiatr. 2013;41:17–26.
26. Gutiérrez-Rojas L, Azanza JR, Bernardo M, Rojo L, Mesa F, Martínez-Ortega JM. Prevalence of metabolic syndrome in Spanish patients with schizophrenia and overweight. The CRESSOB Study. Actas Esp Psiquiatr. 2014;42:9–17.
27. Aguilar E, Coronas R, Caixàs A. [Metabolic syndrome in patients with schizophrenia and antipsychotic treatment]. Med Clin (Barc). 2012;139:542–546. Spanish.
28. Khalil R. The metabolic syndrome and schizophrenia: a comorbidity or an association? J Pharmacol Pharmacother. 2013;4:174–175.
29. Chen SF, Huc TM, Lan TH, Chiu HJ, Sheen LY, Loh EW. Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: severe negative syndrome may be related to a distinct lipid pathophysiology. Eur Psychiatry. 2014;29:167–171.
30. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42:125–147.
31. Steylen PM, van der Heijden FM, Kok HD, Sijben NA, Verhoeven WM. Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment. Int J Psychiatry Clin Pract. 2013;17:125–130.